OncLive TV

Tianhong (Tina) Li, MD, PhD, from the UC Davis Comprehensive Cancer Center, discusses results from the LUX-Lung 3 trial that examined afatinib as a first-line treatment for patients with EGFR-positive advanced lung adenocarcinoma.

William J. Gradishar, MD, from the Northwestern University Feinberg School of Medicine, reviews results from the phase III LEA trial that investigated add-on bevacizumab in breast cancer.

Smita Bhatia, MD, MPH, Population Sciences, City of Hope, Duarte, California, explains a clinical trial analyzing genetic susceptibility to anthracycline-related congestive heart failure in survivors of hematopoietic cell transplantation.

Michelle A. Fanale, MD, from the MD Anderson Cancer Center, discusses a phase I trial that examined the frontline administration of brentuximab vedotin for patients with subtypes of lymphoma.

Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute and Brigham and Women's Hospital, discusses trials investigating cabozantinib in breast cancer.

Brian G. M. Durie, MD, Cedars-Sinai Medical Center, Senior Advisor, Hematologic Malignancies, National Program Director, Multiple Myeloma and Related Disorders for Aptium Oncology, discusses novel therapies for multiple myeloma.

David Schuster, MD, director, from Emory University, compares the efficacy of bone scans and FDG-PET/CT scans for detecting bone metastases in patients with breast cancer.

Corey J. Langer, MD, from the University of Pennsylvania, Abramson Cancer Center, discusses the EGFR-targeted tyrosine kinase inhibitor erlotinib for patients with non-small cell lung cancer.

Andrew D. Zelenetz, MD, PhD, from the Memorial Sloan-Kettering Cancer Center, explains the impact that rituximab has made in the treatment of patients with non-Hodgkin and B-cell lymphomas.

Randall F. Holcombe, MD, Tisch Cancer Institute at Mount Sinai Medical Center, speaks about the use of aflibercept in patients with metastatic colorectal cancer.

Debu Tripathy, MD, from the USC Norris Comprehensive Cancer Center, discusses a phase II trial that examined the CDK inhibitor PD 0332991 for women with advanced estrogen receptor-positive breast cancer.

Matthew H.G. Katz, MD, from the MD Anderson Cancer Center, discusses borderline resectable pancreatic ductal adenocarcinoma, a newer stage of pancreatic cancer introduced by the NCCN in 2003.

Srikala Sridhar, MD, MSc, from the University of Toronto, Canada, discusses the results of a single arm phase II trial examining nab-paclitaxel as a secondary treatment for urothelial cancer.

Don S. Dizon, MD, Assistant in Medicine, Medical Gynecologic Oncology, Massachusetts General Hospital, explains the relationship between PTEN mutations and mTOR inhibitors in endometrial cancer.

Francisco Cervantes, MD, PhD, Hospital Clinic, IDIBAPS, Barcelona, Spain, discusses the initial and long-term findings of the COMFORT-II trial of ruxolitib for the treatment of myelofibrosis.

Edith A. Perez, MD, from the Mayo Clinic Cancer Center, Florida, discusses the results of a phase III study comparing the efficacy of eribulin mesylate to capecitabine in patients with locally advanced or metastatic breast cancer.

Mark G. Kris, MD, chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, discusses the importance of accurately determining a patient's performance status.

William K. Oh, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, discusses ongoing research into combination strategies for men with castration-resistant prostate cancer.

Scott Gettinger, MD, associate professor of medicine (medical oncology), Yale School of Medicine, explains the development of immunotherapies in lung cancer.

Marshall Posner, MD, from Mount Sinai Medical Center, discusses the factors that improve the prognosis for patients with HPV-positive head and neck cancer when compared to patients who are HPV-negative.

William J. Gradishar, MD, from the Northwestern University Feinberg School of Medicine, discusses results from the international ATLAS study that was presented at the 2012 San Antonio Breast Cancer Symposium.

Timothy P. Hughes, MD, MBBS, explains the two-year follow-up results of the ENESTcmr trial analyzing the switch to nilotinib after at least 2 years on imatinib in patients with chronic phase chronic myeloid leukemia.

Mark J. Levis, MD, PhD, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses the design and results of a phase II trial of quizartinib in patients with FLT3-ITD positive or negative relapsed/refractory AML.

Sundar Jagannath, MD, discusses the use of pomalidomide (POM) in relapsed or refractory multiple myeloma.

Cristi Radford, MS, CGC, from the Sarasota Memorial Hospital, discusses examining cancer gene panels using next generation sequencing for patients with ovarian cancer.

Frank delaRama, RN, MS, AOCNS®, from the Palo Alto Medical Foundation, explains the role of oncology nurse navigators in providing relevant information to men with prostate cancer.

Meir Wetzler, MD, explains the CALGB 10001 study analyzing autologous and allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.

Giancarlo Agnelli, MD, University of Perugia, Perugia, Italy, discusses the results of a study comparing the efficacy and safety of two doses of apixaban, an oral factor Xa inhibitor, with placebo for the treatment of venous thromboembolism.

Sung W. Choi, MD, Assistant Professor, University of Michigan, discusses the results of a phase I/II trial examining the use of the histone deacetylase (HDAC) inhibitor vorinostat in graft-versus-host disease (GVHD) prevention.

Jorge E. Cortes, MD, from the MD Anderson Cancer Center, describes results from a 12 month follow up of the phase II PACE study that examined ponatinib in patients with CML and Ph+ ALL.